Term Paper on "Sexual Dysfunction Caused by the Use of Antidepressant Medications"

Term Paper 8 pages (2648 words) Sources: 0

[EXCERPT] . . . .

Pharmaceutical drugs have become the first line of defense against depression, anxiety, and other psychological problems for a majority of patients. As they have become generally safer and more socially widespread, certain side effects have begun to attract a great deal more attention than they had previously. Currently the attention of many researchers is being drawn to the issue of iatrogenic sexual disorders caused by antidepressants and other psychotropic drugs. It appears that many such medicines may cause mild to severe sexual dysfunction as a class side effect. This appears to be especially true of selective serotonin reuptake inhibitors [SSRIs]. A number of other drugs have been suggested to either replace SSRIs as the drug of choice for young, sexually active patients, or to help ameliorate the side effects of traditional psychotropics. There are many barriers to research in this area, including the lack of prior clinical studies and a lack of comprehensive knowledge about the biology of depression and the biology of sexual desire and functioning, and patient hesitance to volunteer information about sexual functioning. However, some steps have been made in remedying these effects. Six recent articles dealing with this topic shed some light on the issue of sexual disfunction and their causes and treatment.

Rivas-Vazquez et al. report on "Psychologists becoming aware of sexual dysfunction with antidepressants."

In 2000 Rivas-Vazquez and his team reported on the increase in interest among researchers on treatment-induced sexual dysfunction, chronicling the many recent discoveries concerning sexual side effects. Though they complained that existing literature dealt mainly with case studies, small-scale trials, and tests which were not randomized and placebo controlled, a rough understanding of the trends did emerge. They found that among the newer generation of antidepressants which had replaced prior, less safe drugs (such as MAOI inhibitors and tricyclics), those which interfered with serotonin levels (SSRIs and venlafaxine) had far more severe sexual side effects than the atypical drugs (bupropion, nefazodone, and mirtazapine) which did not directly effect serotonin.

Rivas-Vazquez et al. record a variety of sexual dysfunctions that may occur as side effects of psychotropics, ranging from unpleasantly increased erectile ability (such as priapism) and unusually high arousal levels to impotence, and delayed or even painful orgasm. The article compiles a list of drugs and effects. The suggest that trazadone has been known to infrequently cause priapism, and that fluoxetine, venlafaxine, and bupropin have all been known to occasionally cause increased libido. However, both venlafaxine and fluoxetine have also been known cause serious sexual dysfunction including decreased sexual desire, inability to function sexually, and decreased orgasmic reactions. Similar negative effects have been discovered in the use of paroxetine, sertraline, and fluvoxamine.

Part of the difficulty in determining exactly what effects drugs are having may be due to the comorbidity of their symptoms with the original psychiatric problems which prompted their use. Depression itself can cause sexual dysfunctions, or create strains in personal relationships which may continue even past the resolution of the illness itself. So, for example, fluoxetine might usually decrease sexual desire physically, but provide such a release from depression that the individual has a higher sex drive than before they became depressed (albeit reduced from a natural baseline which they may never have fully experienced, or may have forgotten). Additionally, the functioning of serotonin and its role in sexual arousal may not be fully understood.

It is generally understood that serotonin does affect sexual functioning by changing the levels of other neurotransmitters which directly control sexual functions at different stages of the sexual style. Dopamine, for example, enhances sexual pleasure and libido, is an intrinsic part of the orgasmic experience and has had some level of the emotional bonding inherent in sex attributed to it. Increased serotonin levels can inhibit dopamine, among other neurotransmitters, which could reduce arousal, libido, and orgasm. Hence SSRIs may necessarily decrease dopamine levels and sexual functioning. Not all antidepressants are equally likely to cause sexual dysfunction, because not all antidepressants directly affect serotonin or dopamine levels.

Rivas-Vasquez et al. suggest that the most appropriate response to unwelcomed sexual side effects in treatment is to consider using atypical antidepressants as the first choice for treating targeted groups of sexually active patients. Careful monitoring of all patients' sexual functioning while on this medication is also strongly recommended, as some patients may hesitate to mention sexual dysfunctions. Through using drugs which have very low incidences of sexual side effects, the degree to which these effects interfere with recovery and with relationships can be minimalized.

Michael Gitlin reports on "Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches"

Like others before him, Gitlin suggests that the sexual side effects of psychotropic drugs are becoming an increasing concern to the clinical and therapeutic community. He blames the emergence of this concern on "gaps in our understanding" regarding both the chemical biology of sexual functioning and the way in which this is affected by Axis I disorders without the intervention of medicine. In pursuit of further knowledge of this subject, Gitlin reviews numerous MEDLINE articles, coming to the conclusion that though clinicians need to be aware of and question their patients regarding sexual side effects, there does not appear to be a specific antidote to these problems clearly indicated by prior research.

Gitilin suggests that clinicians need to evaluate their patient's sexual functioning based on all possible causation for existing problems. Though dopamine is generally understood to increase sexual functioning which serotonin decreases it and norepinephrine has mixed effects, there appear to be negative sexual side effects associated with all psychotropic classes. Neuroleptics can cause priapism. Anxiolytics and mood stabilizers boast an array of mild, effects. SSRIs, clomipramine and MAO inhibitors can cause severe side effects, while others like the tricyclics cause more mild effects.

There are a variety of possible, though not entirely proven, tactics which may be taken to reduce iatrogenic sexual disorders. These tactics include attempting to out-wait the symptoms and hope they go away, switching to a different drug, and lowering the dose to provide less effect. Additionally, a few antidotes have been proposed, including yohimbine and cyproheptadine, which may reverse problems with sexual side effects. Gitilin reasonably suggests that lowering the dose, attempting to outwait the effects, and using antidotes should all be attempted before abandoning a drug that works well for the patient's symptoms. Hopefully, in the future there will be more and better research on antidotes.

Nafziger et al. report on the "Incidence of sexual dysfunction in healthy volunteers on Fluvoxamine therapy"

Because of the problems, noted by prior researchers, regarding discriminating the differences between the symptoms of mental illness and the side effects of psychotropics used to cure those illnesses, Nafziger and his colleagues chose to conduct a study on the side effects of the antidepressant fluvoxamine on healthy volunteers. Prior research on fluvoxamine had suggested that only 1% to 8% of patients using this drug would experience sexual dysfunction. Considering that other SSRIs had reported sexual side effect rates up to 75%, these very low numbers might encourage many people to switch to fluvoxamine. Nafziger points out that this prior research had, however, depended on self-reporting of sexual dysfunction, which might discourage embarrassed individuals from mentioning their problems. The present study closely monitors effects and questions patients regarding their experiences with fluvoxamine.

In this study, among healthy volunteers who took 150mg of fluvoxamine daily, 20% experienced sexual dysfunctions within two weeks, and 35% experienced sexual dysfunction within four weeks. This was much higher than previously assumed, and this rate was comparative to the experiences of patients on SSRIs, and (according to this article) that of tricyclic and heterocyclic antidepressants and MAOIs.

The fact that this study found much higher than expected rates of sexual side-effects from fluvoxamine than was expected highlights the importance of specifically asking individuals about their experiences in determining rates of sexual side effects, rather than depending on self-reporting. One might have expected that fluvoxamine, being an SSRI, would have many of the same side effects of other SSRIs, but the fact that otherwise had been suggested is importance to notice.

Michelson et al. report on "Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacological intervention"

One of the main frustrations among researchers in this field is the lack of double-blind and placebo-controlled studies. The importance of having such studies is highlighted by Michelson et al.'s controlled trial assessing the results of supplementing fluoxetine with buspirone or amantadine (or a placebo) for a period of time. Michelson found that though uncontrolled case studies had suggested that such supplements could help with female iatrogenic sexual dysfunction, in his own study it appeared that though buspirone and amantadine worked to improve most of the patient's conditions, a placebo worked equally well. As the article explains, "The mechanisms underlying this improvement are uncertain but probably relate to the intensive self-monitoring of sexual function and regular clinic visits as well as to nonspecific effects associated with medication administration."

Some evidence that buspirone… READ MORE

How to Reference "Sexual Dysfunction Caused by the Use of Antidepressant Medications" Term Paper in a Bibliography

Related Term Papers:

Effect of Traumatic Brain Injury on Sexual Function Term Paper

Traumatic Head Injury on Sexual Function

Sexual Dysfunction Caused by Traumatic Brain Injury

Traumatic brain injury has a number of well documented long-lasting after effects which can inhibit the normal… read more

Term Paper 8 pages (2181 words) Sources: 1+ Topic: Sexuality / Gender

---

Children, Grief, and Attachment Theory Term Paper

Children, Grief, And Attachment Theory

When a child, age 7 to 11, experiences the death of a nuclear or extended family member, the experi-ence generates subsequent grief reaction/s. During the… read more

Term Paper 75 pages (22384 words) Sources: 40 Topic: Child Development / Youth / Teens

---

Treatment of Women Diagnosed With Dysthymia Term Paper

Treatment of Women Diagnosed With Dysthymia

This proposal for a clinical case study of the treatment of a woman diagnosed with dysthymia employs a cognitive behavioral approach to identifying effective… read more

Term Paper 48 pages (13264 words) Sources: 1+ Topic: Psychology / Behavior / Psychiatry

---

Compulsive Hoarding Due to Childhood Sexual Abuse Term Paper

Compulsive Hoarding Due to Childhood Sexual Abuse

The objective of this work is to research and examine childhood sexual abuse and compulsive hoarding. This work will identify the social impediments… read more

Term Paper 15 pages (4019 words) Sources: 6 Style: APA Topic: Psychology / Behavior / Psychiatry

---

Borderline Personality Disorder Definitions and Historical Foundations Term Paper

Borderline Personality Disorder

Definitions and historical foundations

Diagnostic and Statistical Manual of Mental Disorders (DSM

Etiology

DBT

Genetics

Environmental Conditions

Neurological issues

Diagnoses and related issues

Comorbidity

Psychopharmacological approaches

Dialectical… read more

Term Paper 45 pages (12483 words) Sources: 1+ Topic: Psychology / Behavior / Psychiatry

---

View 100+ more related papers  >>